PROTEIN VACCINE AGAINST NEONATAL GROUP B STREPTOCOCCAL INFECTION Immunization experiments in animals and a serological study in humans
Infection with group B streptococcus (GBS), an encapsulated bacterium, is an important cause of neonatal morbidity and mortality. Capsular polysaccharides and cell surface proteins of GBS are candidate antigens for development of a human GBS vaccine. Proteins have many advantages as vaccine antigens. The majority of the neonatal infections are caused by strains of capsular serotypes Ia, Ib, II, II
